Transcend Therapeutics, a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases, announced on Friday the completion of its acquisition by Otsuka America Inc, a subsidiary of Japanese healthcare company Otsuka Pharmaceutical Co Ltd.
The acquisition was originally announced in March 2026. Transcend is now a wholly owned subsidiary of Otsuka America Inc.
TSND-201 (methylone), a rapid-acting neuroplastogen being developed by Transcend, demonstrated favourable results in IMPACT-1, its Phase 2 clinical trial, with results published in JAMA Psychiatry. In 2025, TSND-201 received FDA Breakthrough Therapy Designation for the post-traumatic stress disorder (PTSD) indication, and earlier this year was awarded an FDA Commissioner's National Priority Voucher, recognising the programme's potential to address a significant unmet need in mental health. A Phase 3 trial with TSND-201 for the treatment of PTSD is currently ongoing.
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain
IceCure reports growing adoption of ProSense cryoablation in Brazil
Aurinia initiates PRESERVE Phase 4 study of LUPKYNIS combination therapy in lupus nephritis
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Neurocrine Biosciences initiates crinecerfont Phase 2 study in young children with classic CAH